Breast Cancer

, Volume 15, Issue 4, pp 256–261 | Cite as

Estrogen signaling pathway and hormonal therapy

Special Feature Current topics in endocrine therapy for breast cancer

Abstract

Hormonal therapy, such as estrogen-targeting therapy, has undergone remarkable development in recent several years, using drugs such as LH–RH agonists, new SERMs and third-generation aromatase inhibitors. Several ongoing large-scale international clinical trials for hormonal therapy are establishing the standard protocol for treatments with these drugs. On the other hand, there have been attempts to predict the individual efficacy of hormonal therapy using classical molecular biomarkers such as ER and PgR. However, approximately one-third of ERα-positive patients do not respond to endocrine therapy, while some ERα-negative patients are responsive. These discrepancies may be due to the different estrogen-related intracellular signaling pathways in breast cancer cells. Furthermore, the ineffectiveness of hormonal therapy in some individuals (due to, for example, aromatase inhibitor resistance) may be caused by these mechanisms. In this paper, we discuss the molecular mechanisms of these different responses to hormonal therapies and their implications for the estrogen signaling pathway in breast cancer cells. Furthermore, we touch upon basic studies into predicting the efficacy of hormonal therapy and new strategies in this field.

Keywords

Estrogen Hormonal therapy SERM Aromatase Phosphorylation 

Intracellular estrogen signaling pathways

Estrogen regulates various physiological responses in many target tissues, and is well known to play important roles in the development and progression of breast cancers [1]. As shown in Fig. 1, estrogen controls the expression of a wide variety of genes through distinct genomic and nongenomic pathways [2, 3]. In the classical genomic pathway, estrogen signals are mediated through the estrogen receptor (ER), which functions as a transcription factor for target genes. Estrogen also regulates the functions of factors in cells through various mechanisms, including protein phosphorylation, involving nongenomic and rapid actions [4]. ERα can be activated by the signal crosstalk between estrogen and growth factors such as epidermal growth factor (EGF) and insulin growth factor-1 (IGF-1) via receptor phosphorylation [5, 6, 7]. Recent findings have revealed that these extremely complicated signaling pathways are triggered by estrogen stimulation.
Fig. 1

Outline of estrogen signaling pathways. Estrogen evokes genomic and nongenomic actions via nuclear ER and membrane-associated ER. Moreover, these signals are also stimulated or modulated by crosstalk with the intracellular protein kinase-mediated phosphorylation signaling cascade

Estrogen signals via ligand-dependent genomic pathways

Estrogen exerts its biological effects by binding to ER, which mainly exists in the nucleus as a member of the nuclear receptor superfamily of transcription factors. ER acts through the formation of homo- or heterodimers of ERα and ERβ, and ERα has been widely used as a predictive marker for hormonal therapy. In the classical pathway, estrogen-bound ERs dimerize and function as a transcription factor which binds to a specific DNA sequence named the estrogen response element (ERE) present in the promoter or enhancer regions of target genes. ER binds to ERE through its DNA-binding domain (DBD) and recruits coactivators such as SRC-1, AIB1 and p300/CBP to form a functional ER complex [8, 9]. It is now known that ER target genes which have full or half ERE sites include pS2, cathepsin D, PgR, Efp, EGR3, etc. [10, 11, 12, 13].

In the genomic pathway, ER can also regulate transcription without binding directly to DNA. ER acts as a coactivator—ER interacts with other transcription factors such as AP-1, SP-1 and NF-κB via protein–protein interactions, and it could regulate the transcription of genes that lack ERE but has a binding element for its partner’s protein. It has been suggested that genes activated in this way include ovalbumin, IGF-1, collagenase, VEGF, c-Myc, cyclin D1, c-fos, NF-κB, and LDL receptor [14, 15, 16].

Activation of ER by protein phosphorylation

Nuclear ERα has several different phosphorylation sites, as shown in Fig. 2, and is targeted by several kinases, including MAPK and PI3K/Akt. In particular, serines 104/106, 118 and 167 are located within the activation function 1 (AF-1) region of ERα, in the A/B domain. Thus, these phosphorylation sites could play an important role in the regulation of AF-1 transcription activity. For example, it has been shown that Ser118 of ERα is a major site of phosphorylation by MAPK cascade, and this phosphorylation exerts or upregulates the estrogen-responsive transcription activity of ERα [17, 18]. Some other reports have shown that PI3k-Akt pathway-stimulating Ser167 phosphorylation is a major estrogen-induced phosphorylation event [19]. It has been reported that this phosphorylation is also provided by the MAPK pathway [20]. Furthermore, phosphorylation signaling pathways are also suggested to stimulate ERα transcription activity through the phosphorylation of coactivators for ERα, such as AIB1, a member of the p160 family [21, 22].
Fig. 2

Phosphorylation sites in ERα. Six amino acid residues have been reported to be phosphorylated in the ERα protein, and various specific protein kinase cascades are involved with their phosphorylation. The phosphorylated protein forms a more stable transcription complex with the coactivators and upregulates the transcription activity of ERα

These alternative ERα activation pathways arising from the intracellular phosphorylation signaling cascade could be related to the clinical response of breast cancer to hormonal therapy. It has recently been reported that the phosphorylation of Ser167 is related to the response to hormonal therapy, based on analysis by an immunohistochemical technique [23]. Although inter-individual differences in the estrogen signaling pathway in breast cancer have not yet been investigated, the analysis of this alternative pathway in patients is important for the personalized treatment of breast cancer in the future. For some ERα-positive cases in which this alternative pathway is dominant, growth factor inhibitors or protein-kinase inhibitors may be useful for combination therapies with hormone (Fig. 3).
Fig. 3

Intracellular cross-talk of the estrogen signaling pathway with the phosphorylation cascade. In addition to ligand-dependent activation, ERα activity is modulated by post-translational modifications through the direct phosphorylation of ERα or coactivators in a ligand-independent manner. ERα activation by growth factors such as EGF, IGF, heregulin and TGF-α has been reported. The activated ER binds to not only ERE but also AP-1 or SP-1 binding elements, together with each specific protein

Estrogen signals via nongenomic pathways

Estrogen also exerts rapid effects that are not accounted for by transcriptional mechanisms. As some signals from several ligands for the steroid receptor superfamily have been shown to be mediated through plasma membrane, there is accumulating evidence to support the idea that estrogen receptors are also located at the plasma membrane and are responsible for extranuclear, rapid and nongenomic actions. The existence of membrane ER has been demonstrated using cell-membrane impermeable BSA-conjugated estradiol [24, 25], although some concerns have been pointed out regarding these agents. Membrane ER has been reported to associate with many growth factor receptors, such as IGF-1R, EGFR, HER2. In the activation of IGF-1R, E2 induces the formation of a ternary complex among ERα, IGF1-R and Shc, the adaptor protein, in the plasma membrane, which induces phosphorylation of IGF-1R [26]. The estrogen-bounded membrane ER rapidly activates several signals in a cell type-specific manner, including calcium currents, cAMP, inositol phosphate, G proteins, Src, and Shc, which leads to the activation of downstream kinases, such as mitogen-activated protein kianse (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt [4].

Although the origin of membrane ER is not completely resolved, most of the evidence supports the idea that the membrane ER is the same protein as the nuclear ER, based on evidence such as the detection of membrane ER by antibodies to nuclear ER and the codetection of membrane and nuclear ERs after nuclear ER cDNA transfection in ER null cells. In either case, the membrane ER was only a small fraction of the total ER. Recently, several reports have suggested that GPR30, a G protein-coupled receptor, is another candidate for the rapid estrogen signals [27, 28]. However, one report indicated that estrogen signals could not be induced in human breast cancer SKBR-3 (ER negative, GPR30 positive) cell signals [29], and further studies are needed to clarify the role of GPR30 in rapid signaling by estrogen at the plasma membrane in breast cancer cells.

ER does not have a transmembrane domain, and is localized at the inner face of the plasma membrane through binding to other proteins such as caveolin-1 [30], the major structural protein of caveolae. Shc and growth factor receptors also facilitate the membrane localization of ER as described above, and the cytoplasmic proteins MTA1-S or MNAR (modulator of the nongenomic activity of ER)/PELP1 can sequester ER outside of the nucleus [31, 32, 33]. Overexpression of HER2 in ER-positive breast cancer cells, which is associated with the development of hormone-resistant breast cancer, promotes the cytoplasmic sequestration of ER, and the interaction of ER with HER2 activates mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 (ERK1/2) [34].

As described above, the molecular mechanism of nongenomic estrogen action has not yet been established. Moreover, the clinical significance of this action has not been assessed in breast cancer, because of methodological issues.

Extracellular factors for estrogen signal stimulation

Recent data have demonstrated that the intercellular communication between tumor and stromal cells profoundly affects the proliferation of breast cancer cells, which is mediated by the production of estrogen, growth factors, chemokines, and cytokines [35, 36, 37]. Among the stromal cells, fibroblasts are the most abundant cell type, and tumor-associated fibroblasts are known to express aromatase, a key enzyme of estrogen synthesis, resulting in the intratumoral estrogen production frequently observed in postmenopausal breast cancers [38, 39]. Aromatase expression levels in breast cancer tissues are significantly higher than those in benign breast lesions. Several reports suggest that the tumor–stromal interaction regulates aromatase gene expression via the production of various factors such as prostaglandin E2, COX2, tumor necrosis factor-α, interleukin-6 and interleukin-11 [40]. Therefore, aromatase is a target of endocrine therapy for breast cancers, and several aromatase inhibitors have been developed to attenuate estrogen biosynthesis, such as anastrozole, letrozole, and exemestane. The recent reports on the efficacies of these drugs again strongly indicate that the estrogen is a crucial factor in the survival of breast cancer [41].

ERE-GFP reporter cells (E10) and estrogen-depletion resistance

To investigate estrogen signaling in breast cancer and in order to improve predictions of the efficacy of aromatase inhibitors for individual breast cancers, we developed a comprehensive system to visualize the ER-activating ability (not only of estrogen, but also of other crosstalk signals, as described above) stimulated by the adjacent microenvironment. We first established a stable transformant, named E10, of human breast cancer MCF-7 cells which had an integrated ERE-GFP reporter gene. These E10 cells express GFP when endogenous ERα is activated. We characterized the stromal fibroblasts of individual breast cancers by establishing a co-culture system with E10 cells, and found that the induced GFP expression varied among the cases, indicating that the stromal fibroblasts in each case had their own properties with respect to the activation of estrogen signals [42].

Furthermore, we recently isolated and established estrogen-depletion resistant (EDR) E10 cells by long-term culture and passage under estrogen-depletion medium. Figure 4 shows the effect of antiestrogen on two established EDR-E10 cells. The 277-1 cells grew well under estrogen-depletion medium, and antiestrogen did not inhibit the cell growth, while the addition of estrogen even upregulated cell growth. On the other hand, the 277-2 cells showed significant growth inhibition with fulvestrant or a high dose of toremifen, and the growth of this cell line was not upregulated by the addition of estrogen. Moreover, they showed substantial ERE-GFP expression, indicating the presence of activated endogenous ERα. These observations evoked interesting speculation that the ERα in the 277-2 cells may be fully activated by an alternative signaling pathway such as a phosphorylation cascade. While the growth of the 277-1 cells is not critically dependent on the action of the estrogen receptor, the estrogen signaling pathway is active. These cell lines could provide a useful model for the study of multiple estrogen signaling pathways and the eligibility of hormonal therapy. The value of selective estrogen receptor modulators (SERMs) for the treatment of breast cancer must be revaluated to include aromatase inhibitor-resistant cases.
Fig. 4

Effect of antiestrogen on the growth of estrogen-depletion resistant (EDR) cells. The EDR cells, which had high ERE transactivation activities, were established from MCF-7-ERE-GFP-E10 cells by passing them through estrogen-depleting medium and cloning them, and then their ERE-GFP activities were monitored. Antiestrogens (toremifene and fulvestrant) were added to the estrogen-depleted culture medium, and the cell growth was assayed after two days. The ERE-GFP activities of cells to which 1 nM estradiol was added were also assayed, and the percentages of positive cells are shown in the plot

Prediction of hormonal therapy

Recent advances in molecular diagnostic tools such as Oncotype DX (Genomic Health Inc.) and MammaPrint (Agendia Inc.) have opened up a new vista for personalized medicine in the future. On the other hand, a more accurate predictive method or a novel predictive biomarker from among ER and PgR is also desired for predicting the individual efficacy of hormonal therapy. To address this issue, we studied the gene expression profiles of estrogen-responsive genes in breast cancer using a DNA microarray technique [43], and further study revealed several candidate genes for assessing response to hormonal therapy [44]. Recently, a molecular signature of neoadjuvant hormonal therapy for ER-positive patients has been reported [45]. The identified 50-gene subset could be useful for monitoring the short-term effects of hormonal therapy on ER-positive cancers. A new predictive biomarker for hormonal therapy may be found in these genes. Further studies using comprehensive techniques such as microarray analysis to search for new biomarkers will be common in the future.

However, these expression analyses are not able to reveal the specific pathway of estrogen signaling in the cells. Other novel methods, such as phosphorylation-specific proteomics or the in vitro bioassay system using GFP that we reported previously [42], will be needed to analyze the signaling pathway at work in individual cancer cells. In order to be able to predict the individual response to aromatase inhibitor or SERMs, the ability to distinguish between a so-called ligand (estrogen)-independent/ERα-dependent signaling pathway and a ligand-dependent/ERα-dependent signaling pathway is crucial.

Conclusion

The estrogen signaling pathway must be closely associated to the efficacy of hormonal therapy. The discrepancy between ERα expression status and response to hormonal therapy probably derives from the different estrogen signaling pathway conditions in the cells. The resistance to aromatase inhibitor or antiestrogen may be also caused by changes in this pathway. The last two decades have revealed the structure and function of the estrogen receptor to be a nuclear transcription factor which controls its target genes and plays an important role in various physiologic functions. However, as described in this paper, there are still many questions about and ambiguities regarding the estrogen signaling pathway. In particular, the elucidation of the mechanism of ligand-independent ER-activation and nongenomic estrogen action is extremely important for translational research in breast cancer. Further studies of the estrogen signaling pathway may provide new clues about the estrogen-dependent mechanisms of breast cancer development, and may dramatically advance the accuracy with which the efficacy of molecular therapeutics can be predicted, as well as new strategies in this field.

References

  1. 1.
    Hayashi S, Eguchi H, Tanimoto K, Yoshida T, Omoto Y, Inoue A, et al. The expression and function of estrogen receptor α and β in human breast cancer and its clinical application. Endocr Relat Cancer. 2003;10:193–202.PubMedCrossRefGoogle Scholar
  2. 2.
    Levin ER. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol. 2005;19:1951–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Björnström L, Sjöberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol. 2005;19:833–42.PubMedCrossRefGoogle Scholar
  4. 4.
    Norman AW, Mizwicki MT, Norman DP. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev. 2004;3:27–41.Google Scholar
  5. 5.
    Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res. 2005;11:865s–70s.PubMedGoogle Scholar
  6. 6.
    Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem. 1994;269:4458–66.PubMedGoogle Scholar
  7. 7.
    Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995;270:1491–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Smith CL, O’Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev. 2004;25:45–71.PubMedCrossRefGoogle Scholar
  9. 9.
    Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, et al. AIB1, a steroid receptor coactivtor amplified in breast and ovarian cancer. Science. 1997;277:965–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Brown AMC, Jeltsch JM, Roberts M, Chambon P. Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc Natl Acad Sci USA. 1984;81:6344–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Westley B and Rochefort H. A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell. 1980;20:353–62.CrossRefGoogle Scholar
  12. 12.
    Inoue S, Orimo A, Hosoi T, et al. Genomic binding-site cloning reveals an estrogen-responsive gene that encodes a RING finger protein. Proc Natl Acad Sci USA. 1993;90:11117–21.PubMedCrossRefGoogle Scholar
  13. 13.
    Inoue A, Omoto Y, Yamaguchi Y, Kiyama R, Hayashi S. Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cell. J Mol Endocrinol. 2004;32:649–61.PubMedCrossRefGoogle Scholar
  14. 14.
    Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, et al. Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem. 2002;277:24353–60.PubMedCrossRefGoogle Scholar
  15. 15.
    Bruning JC, Lingohr P, Gillette J, Hanstein B, Avci H, Krone W, et al. Estrogen receptor-alpha and Sp1 interact in the induction of the low density lipoprotein-receptor. J Steroid Biochem Mol Biol. 2003;86:113–21.PubMedCrossRefGoogle Scholar
  16. 16.
    Kalaitzidis D, Gilmore TD. Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends Endocrinol Metab. 2005;16:46–52.PubMedCrossRefGoogle Scholar
  17. 17.
    Kato S, Masuhiro Y, Watanabe M, Kobayashi Y, Takeyama K, Endoh H, et al. Molecular mechanism of a cross-talk between oestrogen and growth factor signalling pathways. Genes Cells. 2000;5:593–601.PubMedCrossRefGoogle Scholar
  18. 18.
    Bunone G, Briand P-A, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996;15:2174–83.PubMedGoogle Scholar
  19. 19.
    Amold SF, Obourn JD, Jaffe H, Notides AC. Ser 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Mol Endocrinol. 1994;8:1208–14.CrossRefGoogle Scholar
  20. 20.
    Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J, Lannigan DA. pp90srk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol. 1998;18:1978–84.PubMedGoogle Scholar
  21. 21.
    Rowan BG, Weigel NL, O’Malley BW. Phosphorylation of steroid receptor coactivator-1: indentification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway. J Biol Chem. 2000;275:4475–83.PubMedCrossRefGoogle Scholar
  22. 22.
    Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol. 2000;20:5041–7.CrossRefGoogle Scholar
  23. 23.
    Yamashita H, Nishino M, Kobayashi S, Ando Y, Sugiura H, Zhang Z, et al. Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res. 2005;7:753–64.CrossRefGoogle Scholar
  24. 24.
    Razandi M, Pedram A, Greene GL, Levin ER. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERα and ERβ expressed in Chinese hamster ovary cells. Mol Endocrinol. 1999;13:307–19.PubMedCrossRefGoogle Scholar
  25. 25.
    Harrington WR, Kim SH, Funk CC, Madak-Erdogan Z, Schiff R, Katzenellenbogen JA, et al. Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. Mol Endocrinol. 2005;20:491–502.PubMedCrossRefGoogle Scholar
  26. 26.
    Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R, Santen RJ. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor α to the plasma membrane. Proc Natl Acad Sci USA. 2004;101:2076–81.PubMedCrossRefGoogle Scholar
  27. 27.
    Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cell. Endocrinol. 2004;146:624–32.CrossRefGoogle Scholar
  28. 28.
    Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, et al. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17β-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004;279:27008–16.PubMedCrossRefGoogle Scholar
  29. 29.
    Pedram A, Razandi M, Levin ER. Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol. 2006;20:1996–2009.PubMedCrossRefGoogle Scholar
  30. 30.
    Razandi M, Oh P, Pedram A, Schnitzer J, Levin ER. ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions. Mol Endocrinol. 2002;16:100–15.PubMedCrossRefGoogle Scholar
  31. 31.
    Barletta F, Wong CW, McNally C, Komm BS, Katzenellenbogen B, Cheskis BJ. Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc. Mol Endocrinol. 2004;18:1096–108.PubMedCrossRefGoogle Scholar
  32. 32.
    Acconcia F, Kumar R. Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett. 2005;238:1–14.PubMedCrossRefGoogle Scholar
  33. 33.
    Kumar R, Wang RA, Mazumdar A, Talukder AH, Mandal M, Yang Z, et al. A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature. 2002;418:654–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Yang Z, Barnes CJ, Kumar R. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor α in breast cancer cells. Clin Cancer Res. 2004;10:3621–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang AH, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004;6:17–32.PubMedCrossRefGoogle Scholar
  36. 36.
    Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121:335–48.PubMedCrossRefGoogle Scholar
  37. 37.
    Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392–401.PubMedCrossRefGoogle Scholar
  38. 38.
    O’Neill JS, Miller WR. Aromatase activity in breast adipose tissue from women with benign and malignant breast disease. Br J Cancer. 1987;56:601–4.PubMedGoogle Scholar
  39. 39.
    Santen RJ, Santner SJ, Pauley RJ, Tait L, Kaseta J, Demers LM, et al. Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible? J Steroid Biochem Mol Biol. 1997;61:267–71.PubMedCrossRefGoogle Scholar
  40. 40.
    Simpson ER, Davis SR. Minireview: aromatase and the regulation of estrogen biosynthesis-some new perspectives. Endocrinology. 2001;142:4589–94.PubMedCrossRefGoogle Scholar
  41. 41.
    Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–2.PubMedCrossRefGoogle Scholar
  42. 42.
    Yamaguchi Y, Takei H, Suemasu K, Kobayashi Y, Kurosumi M, Harada N, et al. Tumor–stromal interaction through the estrogen-signaling pathway in human breast cancer. Cancer Res. 2005;65:4653–62.PubMedCrossRefGoogle Scholar
  43. 43.
    Inoue A, Yoshida N, Omoto Y, Oguchi S, Yamori T, Kiyama R, et al. Development of cDNA microarray for expression profiling of estrogen-responsive genes. J Mol Endocrinol. 2002;29:175–92.PubMedCrossRefGoogle Scholar
  44. 44.
    Yoshida N, Omoto Y, Inoue A, Eguchi H, Kobayashi Y, Kurosumi M, et al. Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. Cancer Sci. 2004;95:496–502.PubMedCrossRefGoogle Scholar
  45. 45.
    Harvell DME, Spoelstra NS, Singh M, McManaman JL, Finlayson C, Phang T, Hunter L, Dye WW, Borges VF, Elias A, Horwitz KB, Richer JK. Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Res Treat. 2008; in press.Google Scholar

Copyright information

© The Japanese Breast Cancer Society 2008

Authors and Affiliations

  1. 1.Department of Molecular and Functional Dynamics, Laboratory Medicine and SciencesTohoku University Graduate School of MedicineSendaiJapan
  2. 2.Research Institute for Clinical OncologySaitama Cancer CenterSaitamaJapan

Personalised recommendations